HIV and HCV co-infection: situation at six French university hospitals in the year 2000.
The aims of this study were to assess the sociodemographic, epidemiological, clinical, and biological characteristics of French patients co-infected with human immunodeficiency virus-hepatitis C virus (HIV-HCV), as well as the management of their HCV infection. Data on 509 HIV-HCV co-infected patients, followed up at six French University Hospitals, were collected using a questionnaire. Student's t-test, Pearson's chi-square, Fisher's exact, and Fisher-Freeman-Halton's exact tests were used. The mean age of the patients was 38.3 years, and the male to female sex ratio 2.08; 88% of patients were born in Metropolitan France, and 20% were dependent on health benefits; 74% were intravenous drug users and 14% blood or blood product recipients. Forty-seven percent were in CDC classification stage A, 18% had a CD4+ count of <200, and 79% were undergoing current antiretroviral treatment. HCV RNA was positive in 84% (50% type 1, 13% untypable). Forty-four percent had normal alanine aminotransferase (ALT) levels, 24% alcohol consumption >15 g/day, and 51% had undergone liver biopsy (10% of which had cirrhosis). Histological grade was not related to ALT level or CD4+ count. Overall, 40% of patients had been treated for HCV infection. HCV treatment was significantly associated with performance of liver biopsy, histological grade, ALT level, CD4+ count, Centers for Disease Control (CDC) classification, but not with age or alcohol consumption. Rate of early response to treatment was fifty percent among patients treated with bitherapy. Eighty-nine percent of all patients with previous or current anti-HCV treatment had undergone liver biopsy. In conclusion, despite the difficulties in managing hepatitis C in HIV-infected patients, almost one-half of all patients in this study had received anti-HCV treatment.
Buffet-Janvresse
Claudine
C
Laboratoire de Virologie, Université de Rouen, Rouen, France. claudine.buffet-janvresse@chu-rouen.fr
Peigue-Lafeuille
Hélène
H
Benichou
Jacques
J
Vabret
Astrid
A
Branger
Michel
M
Trimoulet
Pascale
P
Goria
Odile
O
Laurichesse
Henri
H
Abbed
Abdelaziz
A
Verdon
Renaud
R
Bouvet
Elisabeth
E
Lafon
Marie-Edith
ME
Dussaix
Elisabeth
E
Cormerais
Louis
L
Dupon
Michel
M
Henquell
Cécile
C
Josse
Annie
A
Lagoutte
Philippe
P
Lariven
Sylvie
S
LeGac
Sylvie
S
Riachi
Ghassan
G
Verdon
Renault
R
Vittecoq
Didier
D
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D005602:France; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D006785:Hospitals, University; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008099:Liver / Q000473:pathology / Q000821:virology*; D008297:Male; D012367:RNA, Viral / Q000032:analysis* / Q000097:blood; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000150:complications*; D011795:Surveys and Questionnaires
D000998:Antiviral Agents; D012367:RNA, Viral; D007372:Interferons; D000410:Alanine Transaminase